153435-80-4

Basic information

• Product Name: 3-BROMO,N, N-DIMETHYLBENZENESULFONAMIDE
• Synonyms: N,N-DIMETHYL 3-BROMOBENZENESULFONAMIDE;3-BROMO,N, N-DIMETHYLBENZENESULFONAMIDE;3-BROMO-N,N-DIMETHYLBENZENESULPHONAMIDE;3-Bromo-N,N-dimethylbenzenesulphonamide 98%;N,N-Dimethyl 3-bromophenylsulfonamide;3-Bromo-N,N-dimethylbenzenesulphonamide98%
• CAS NO: 153435-80-4
• Molecular Formula: C₈H₁₀BrNO₂S
• Molecular Weight: 264.14
• Product Categories: blocks;Bromides;Sulfonamides;Aryl;Organohalides;Sulfonamide;alkyl bromide
• Mol File: 153435-80-4.mol

Chemical Properties

• Melting Point: 74-78
• Boiling Point: 340.3 °C at 760 mmHg
• Flash Point: 159.6 °C
• Appearance: /
• Density: 1.543 g/cm³
• Vapor Pressure: 8.66E-05mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 3-BROMO,N, N-DIMETHYLBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO,N, N-DIMETHYLBENZENESULFONAMIDE(153435-80-4)
• EPA Substance Registry System: 3-BROMO,N, N-DIMETHYLBENZENESULFONAMIDE(153435-80-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 153435-80-4(Hazardous Substances Data)

Usage

Uses

Used in Industrial and Agricultural Applications:
3-Bromo-N,N-dimethylbenzenesulfonamide is used as a mildewcide and fungicide for controlling various types of mold. Its effectiveness in combating mold growth makes it a valuable asset in both industrial and agricultural settings, where mold and fungal infestations can lead to significant losses.
Used in Pharmaceutical Synthesis:
As an intermediate in the synthesis of pharmaceuticals, 3-Bromo-N,N-dimethylbenzenesulfonamide plays a crucial role in the development of new drugs and organic compounds. Its chemical properties allow it to be a building block for creating a wide range of medicinal agents, contributing to advancements in healthcare and medicine.
Used in Chemical Research:
3-Bromo-N,N-dimethylbenzenesulfonamide is also utilized in chemical research for studying the properties and reactions of sulfonamides and related compounds. Its unique structure and reactivity make it an interesting subject for scientific investigations, potentially leading to new discoveries and applications in the field of chemistry.
Safety Precautions:
It is important to handle 3-Bromo-N,N-dimethylbenzenesulfonamide with care due to its potential hazards. Ingestion, inhalation, and skin or eye contact can cause harm, and therefore, appropriate safety measures should be taken during its use and storage. Proper protective equipment and handling procedures are essential to minimize the risk of adverse effects.

InChI:InChI=1/C8H10BrNO2S/c1-10(2)13(11,12)8-5-3-4-7(9)6-8/h3-6H,1-2H3

Upstream product

• 153435-79-1 N-methyl-3-bromobenzenesulfonamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 
• 124-40-3 dimethyl amine 

Downstream Products

• 153435-33-7 N,N-dimethyl-3-tributylstannylbenzenesulfonamide 
• 486422-05-3 N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide 
• 1240285-86-2 {4-chloro-2-[(3-dimethylaminosulfonylphenyl)ethynyl]phenoxy}acetic acid 
• 452340-00-0 3-[4-({6-[(5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-2-oxo-1,3-oxazolidin-3-yl]hexyl}oxy)but-1-ynyl]-N,N-dimethylbenzenesulfonamide 
• 288571-54-0 3-[3-(2-methoxymethylene-cyclohexyl)-propionyl]-N,N-dimethyl-benzenesulfonamide 

Relevant articles and documents

Rational Design and Synthesis of Selective PRMT4 Inhibitors: A New Chemotype for Development of Cancer Therapeutics**

Protein arginine N-methyl transferase 4 (PRMT4) asymmetrically dimethylates the arginine residues of histone H3 and nonhistone proteins. The overexpression of PRMT4 in several cancers has stimulated interest in the discovery of inhibitors as biological tools and, potentially, therapeutics. Although several PRMT4 inhibitors have been reported, most display poor selectivity against other members of the PRMT family of methyl transferases. Herein, we report the structure-based design of a new class of alanine-containing 3-arylindoles as potent and selective PRMT4 inhibitors, and describe key structure–activity relationships for this class of compounds.

HSD17B13 INHIBITORS AND USES THEREOF

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH,

Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)

High serum fatty acid (FA) levels are causally linked to the development of insulin resistance, which eventually progresses to type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin resistance and NAFLD. In this article, we report about structure–activity relationship (SAR) studies of small molecule inhibitors of murine ATGL which led to the development of Atglistatin. Atglistatin is a specific inhibitor of murine ATGL, which has proven useful for the validation of ATGL as a potential drug target.

Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models

Optimization of the previously reported benzothiazine analogue A led to the identification of compound 1, which showed anti-convulsant activity in two golden standard animal models of seizure, the MES and scPTZ models. Structure-activity relationship investigation of compound 1 revealed compounds 2, 6 and 19 as attractive anti-epileptic drug (AED) candidates with potent anticonvulsant effect in both the MES and scPTZ models. As these compounds are structurally different from existing AEDs, determination of their mechanism of actions could provide clues to understanding current therapy-resistant seizures. Moreover, these simple phenylsulfoneamide compounds could be good starting points for searching broad spectrum AEDs by such in vivo screening.

Selective methylation of NH-containing heterocycles and sulfonamides using n, N -dimethylformamide dimethylacetal based on calculated pKa Measurements

The use of N,N-dimethylformamide dimethylacetal (DMF-DMA) as a suitable methylating agent for the methylation of NH-containing groups and heterocycles has been investigated. Use of ReactArray and calculated pKa measurements have allowed additional helpful information to be collated to determine optimum reaction conditions for a variety of substrates.

IMIDAZOLE DERIVATIVE

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, R1 represents optionally substituted lower alkyl or the like; R2 represents optionally substituted cycloalkyl or the like; R3 represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.

Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating arylsulfonamide groups

A series of saligenin alkoxyalkylphenylsulfonamide β2 adrenoceptor agonists were prepared by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection. The meta-substituted primary sulfonamide was more potent than the paraand the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues. The onset and duration of action in vitro of selected compounds was assessed on isolated superfused guinea pig trachea. Sulfonamide 29b had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus. Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation. Crystalline salts of 29b were identified that had suitable properties for inhaled administration. A proposed binding mode for 29b to the β2-receptor is presented.

FUSED RING HETEROCYCLE KINASE MODULATORS

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Antimalarial sulfide, sulfone, and sulfonamide trioxanes

A series of trioxanes featuring sulfide, sulfone, and sulfonamide substituents in diverse positions has been prepared. Structure-activity relationship (SAR) generalizations highlight two major factors controlling the antimalarial potency of these new chemical entities: (1) the proximity of the sulfur-containing substituent to the crucial peroxide bond and (2) the oxidation state of the sulfur-containing substituent. Generally, sulfones are more antimalarially potent than the corresponding sulfides. Copyright (C) 2000 Elsevier Science Ltd.